Anbio CEO to Present Product Pipeline and Strategy at March 18 Healthcare Forum
Anbio Biotechnology's CEO will join a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, presenting business updates, strategic initiatives, and product development plans. The company highlights its global IVD portfolio spanning infectious disease to pharmacogenomics, aiming to advance rapid diagnostics and expand investor engagement.
1. Forum Participation Details
On March 18, 2026, Anbio’s CEO will participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcare Forum, outlining the company’s recent business developments, strategic roadmap, and upcoming product milestones to investors and analysts.
2. Global IVD Portfolio and Strategic Goals
Anbio offers a diversified in-vitro diagnostics portfolio covering infectious diseases, cancer, cardiovascular disorders, pharmacogenomics and more, with platforms compatible with serum, plasma, whole blood, urine and saliva. The company aims to broaden access to rapid, cost-effective diagnostics and drive long-term value through innovation and expanded market engagement.